Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review

Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of fatty liver, characterized by the accumulation of fat in the hepatocytes in the absence of alcohol consumption. The spectrum of this disease ranges from steatosis to hepatitis and fi nally cirrhosis and hepatocellular carcinoma. NAFLD pathogenesis is not completely understood but various risk factors like obesity, insulin resistance, and metabolic syndromes have been identifi ed. With the rapid increase in obesity and diabetes during the past decade, the incidence of NAFLD is on the rise and is predicted to become the most common indication for liver transplantation in the future.